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oil occlusion for patent ductus arteriosus (PDA), 
which was first described in 1992,1 has now become 
an established therapy as a transcatheter closure 
technique. In Japan, coil occlusion for PDA has been used 
since 1995.2–4 Various techniques for coil occlusion have 
been developed,5–9 and other types of occlusion systems, 
especially the Amplatzer duct occluder, have been accepted 
as a safe and effective device worldwide.10–14 However, this 
device was not available in Japan until 2009.
Although the efficacy and safety of coil occlusion have 
been reported in many patients with PDA,15–19 there are only 
a few reports on the long-term outcome of coil occlusion. 
Here, we analyzed the long-term outcome of patients with 
PDA who underwent coil occlusion in 3 pediatric institu-
tions in Japan.
Methods
From January 1995 to December 2009, a total of 310 trans-
catheter occlusions were performed in 298 patients with 
PDA at the Ehime University Hospital, Ehime Prefectural 
Central Hospital, and National Cardiovascular Center. In 
accordance with the Declaration of Helsinki, all procedures 
were performed after written informed consent was obtained 
from each patient or family. The 0.038-inch and 0.052-inch 
Gianturco coils and/or detachable PDA coils were used for 
implantation. Patients with transcatheter occlusions for 
which the Redel device20 should be used were excluded, 
because most pediatric cardiologists have no experience 
using this device and it is no longer available in Japan. The 
characteristics of each patient were obtained from their medi-
cal records. The duct shape was categorized according to 
the angiographic classification by Krichenko et al.21 The 
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Background:  Coil  occlusion  has  been  widely  indicated  for  the  closure  of  patent  ductus  arteriosus  (PDA). 
Although many reports have shown the efficacy and safety of coil occlusion, the long-term outcome in patients 
remains controversial. Here, we analyzed the long-term outcome of coil occlusion in patients with PDA in Japan.
Methods and Results:  We collected  the  longitudinal data of patients who underwent coil occlusion between 
1995 and 2009. A total of 310 coil occlusions were performed in 298 patients with PDA. The median minimum 
duct diameter was 1.4 mm. Successful coil occlusion was achieved  in 286 patients  (96.0%), and  total adverse 
events were seen in only 28 cases (9.0%). The median follow-up period was 50 months. The occlusion rates at 
1 month,  6 months,  1 year,  2 years and 5 years were 90.1%, 94.4%, 97.4%, 97.8% and 97.8%,  respectively. 
Patients with a large PDA (≥4 mm) showed a higher rate of residual leakage than those with a small (<2 mm) or 
moderate (2–4 mm) PDA (P=0.004). Patients who underwent this procedure in the early study period also showed 
a higher rate of residual leakage than those in the late study period.
Conclusions:  Coil occlusion is an effective procedure for patients with PDA. Our data indicate that the long-
term outcome is promising without any adverse events.    (Circ J  2011; 75: 407 – 412)
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minimum duct diameter of the PDA was measured on the 
lateral projection of the aortogram. Adverse events were 
defined as follows: failure to implant the coils, coil migra-
tion, accidental detachment of the coil, deformity of the 
delivery cable, difficulty in retrieving the device, coil frac-
ture, hemolysis, peripheral pulmonary stenosis (Doppler 
velocity >2.0 m/s), coarctation associated with the coils, 
residual leakage and recanalization. All patients were fol-
lowed up at 1 month, 6 months, 12 months and every year 
after the procedure. Echocardiography was performed using 
several types of machines, mainly Vivid 5, Vivid 7 (General 
Electric, Vingmed Ultrasound, Horten, Norway), Sonos 
5500 (Philips Technology, Andover, MA, USA), Prosound 
5500 and Prosound 6500 (ALOKA, Tokyo, Japan) with sev-
eral types of probes. Residual leakage of the PDA was eval-
uated by using color-coded Doppler echocardiography. To 
evaluate the effects of left ventricular volume reduction, the 
index of left ventricular end diastolic diameter index 
(LVEDDI: left ventricular end diastolic diameter divided by 
body surface area) and cardiothoracic ratio (CTR) was esti-
mated using echocardiography and chest X-ray, respectively, 
before and after 1 year after the procedure and compared 
using the paired t-test. Long-term occlusion rates after coil 
implantation were analyzed by the Kaplan-Meier method. 
The PDAs were categorized according to their size as small 
(<2 mm), moderate (2–4 mm), and large (≥4 mm).
Results
A total of 310 cardiac catheterizations were performed in 298 
patients between 1995 and 2009. The characteristics of these 
310 catheterizations are summarized in Table. Coil occlu-
sion was performed in 103 patients from 1995 to 2000 (early 
study period), whereas 207 patients underwent catheteriza-
tion from 2001 to 2009 (late study period). The angiographic 
appearance of the ductus was type A in 197 patients, type B 
in 8 patients, type C in 13 patients, type D in 8 patients, type 
E in 28 patients and unknown or unclassified in 32 patients. 
A majority of the patients had an isolated duct (n=276), but 
22 had other cardiac defects, namely, aortic valve disease 
(n=7), atrial septal defect (n=5), ventricular septal defect 
(n=3), pulmonary valve stenosis (n=2), mitral regurgitation 
(n=2), atrioventricular septal defect (n=1), double outlet right 
ventricle (n=1) and coronary artery fistula (n=1). Twenty-one 
patients had chromosomal anomalies: 19 patients on chromo-
some 21 (trisomy 21), 1 patient on chromosome 4 (4q-) and 1 
patient on chromosome 22 (del 22.q.11.2).
The coil occlusion was performed under general anesthe-
sia in 73 patients (30%) and under mild sedation or while 
awake in the other patients. The catheter approach was arte-
rial in 181 procedures (58%), venous in 43 procedures 
(14%), a combination of arterial and venous in 71 proce-
dures (23%) and unknown in 15 procedures (4%). Implanta-
tion was attempted using the detachable PDA coil in 165 
procedures (53%), the Gianturco coil in 75 procedures (24%) 
and a combination of both coils in 35 procedures (11%), 
while the type of coil used was not reported for 35 proce-
Figure 1.    Outcome of 298 patients receiving coil occlusion for patent ductus arteriosus.
Table. Patient Demographics
Median (range)
Sex (M/F) 90/196
Age (years) 5.0 (0.7–74)　　　
Height (cm) 106.0 (60.0–181.3)
Body weight (kg) 18.1 (5.9–99.1)　　
PDA minimum diameter (mm) 2.0 (0.3–5.6)　　
Cardiac index 3.9 (1.4–8.9)　　
Qp/Qs 1.2 (1.0–10.6)
Krichenko classification (A/B/C/D/E/Others) 197/8/13/8/28/32
PDA, patent ductus arteriosus.
409
Circulation Journal  Vol.75,  February  2011
Long-Term Outcome of Coil Occlusion in PDA Patients
Figure 2.    Rate  of  residual  leakage 
after coil implantation for patent duc-
tus  arteriosus  in  298  patients.  The 
rate  of  residual  leakage was  calcu-
lated with the Kaplan-Meier method.
Figure 3.    Rates of  residual  leakage 
in 3 groups with different sized pat-
ent ductus arteriosus (PDA). The rate 
of residual leakage was significantly 
associated with  the size of  the PDA 
(small,  <2 mm;  moderate,  2–4 mm; 
large, ≥4 mm).
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dures. The number of coils implanted in each procedure was 
1 in 174 patients, 2 in 84 patients, 3 in 23 patients, ≥4 in 7 
patients and unknown in 4 patients.
Figure 1 shows the outcome of implantation in 298 
patients. The procedure was successful in 286 patients 
(96.0%) and unsuccessful in 6 (2%); implantation failed in 2 
procedures, and the remaining 4 patients did not undergo 
implantation because the size or shape of the duct was 
unsuitable. Among the patients who did not undergo coil 
implantation, 2 underwent surgical closure, 1 received fur-
ther intervention with the Amplatzer duct occluder and 1 did 
not receive further therapy and was only observed because 
the size of the ductus was too small to insert a guidewire. 
Two patients with other congenital heart disease were 
observed because it was difficult to implant the coil due to 
the size or shape of the PDA.
Adverse events were seen in 27 patients (9%) during 
(n=10) or after (n=17) the procedure. No death and emergent 
surgical intervention was reported. During the procedure, 
migration was observed in 3 cases, accidental detachment of 
the coils in 2 cases, deformity of the coil in 1 case, coil frac-
ture in 1 case and difficulties in retrieving the device in 3 
cases. There was no relationship between the frequency of 
adverse events and the size of the PDA. All migrated coils 
were retrieved, but 1 coil was partially fractured and parts of 
the fractured coil remained in the peripheral pulmonary 
artery. All patients in whom the coils accidentally detached 
or were difficult to retrieve recovered without complications. 
Adverse events after the procedure consisted of hemolysis in 
3 patients, coarctation of the aorta in 1, peripheral pulmo-
nary stenosis (PPS) in 6, transient atrial flutter in 1, coil 
fracture (as seen on the roentgenogram) in 1 and residual 
leakage of the PDA in 5. No recanalization was reported in 
any patient. Among the patients who did not received coil 
occlusion therapy, only 1 developed infective endocarditis, 
whereas no infective endocarditis was observed among the 
patients who did not receive coil occlusion therapy.
The incidence rate of residual leakage after implantation 
is shown in Figure 2. The median follow-up period was 50 
months, and the occlusion rate at 1 month, 6 months, 1 year, 
2 years and 5 years was 90.1%, 94.4%, 97.4%, 97.8% and 
97.8%, respectively. Analysis of risk factors revealed that 
the incidence of final occlusion was significantly higher in 
patients with a small PDA than in those with a moderate or 
large PDA (P=0.004) (Figure 3). The occlusion rate in 
patients who received coil implantation was also higher in 
patients who underwent the procedure in the late study 
period (from 2001 to 2009) than in those in the early study 
period (from 1995 to 2000) (P=0.04), although the final 
occlusion rate was similar (97.0% vs. 98.0%) (Figure 4). The 
LVEDDI and CTR were significantly diminished (43.4 [1.5] 
vs. 35.3 [1.5]; P=0.0002 and 49.5 [0.3%] vs. 47.0 [0.4%]; 
P<0.0001, respectively).
Discussion
Coil occlusions have been used for patients with PDA since 
1992.1 Various types of devices have been developed; how-
ever, the detachable PDA coil and Gianturco coil have been 
widely accepted.5–8 Since the Amplatzer duct occluder was 
Figure 4.    Rate  of  residual  leakage 
and the timing of coil implantation in 
298  patients.  The  rate  of  residual 
leakage  was  associated  with  the 
timing of coil implantation.
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not available during this study period in Japan, coil implanta-
tion was a standard therapy of transcatheter occlusion of 
PDA. Many reports have demonstrated the efficacy and safety 
of coil implantation for PDA with limited results because of 
the short-term observation.15–19 There are only a few reports 
on the long-term outcome of coil occlusion for PDA.22–24
Our study demonstrated that coil occlusion shows long-
term efficacy and safety for patients with PDA. The final 
occlusion rate was 97.8% without any severe adverse events. 
A large PDA was associated with a higher rate of residual 
leakage, but we did not observe a relationship between the 
frequency of adverse events and PDA size. Patients in whom 
coil implantation was performed in the late study period 
showed a better occlusion rate than those in the early study 
period, although the final occlusion rate was similar in the 2 
study periods. In addition, the incidence of adverse events 
during and after the procedure was not high (9%). Although 
this study was retrospective and the indication or techniques 
for the procedure varied among institutions, the results of 
the occlusion rates were similar among them. Therefore, our 
data can be used to evaluate the long-term outcome of coil 
occlusion in patients with PDA.
In our study, the mean follow-up period was 4.2 years and 
137 patients were followed up for over 5 years. No adverse 
events occurred 5 years after coil implantation. Patel et al22 
and Hofbeck et al23 reported long-term results in PDA coil 
occlusion with different procedures; the former used only 
the Gianturco coils and the latter used detachable coils. We 
demonstrated the long-term outcome of the procedures with 
both coils, which can be considered as a generally accepted 
therapy. Magee et al24 demonstrated that the incidence rate 
of residual leakage was 5% and 4% at 1 and 2 years after the 
procedure, respectively. The incidence rate of residual leak-
age in our study was 3.6% and 2.4% at 1 and 2 years after 
the procedure, respectively. Moreover, the follow-up period 
was only 24 months in the study by Magee et al compared 
with our long-term period of 50 months.
The rate of adverse events was 8.7% in our study, which 
is similar to that reported in previous studies (3–10%).16,22–24 
The most frequent adverse event was PPS, but PPS is not an 
indication for further intervention in all patients. No patients 
with adverse events needed an emergency operation or inten-
sive care unit admission in our study. Appropriate proce-
dures and therapy after adverse events probably resulted in a 
favorable outcome for the patients.
In patients with successful implantation, the rate of resid-
ual leakage was very low. However, a higher rate of residual 
leakage was observed in patients with a moderate or large 
PDA. In moderate or large PDAs, other methods such as the 
insertion of an alternative device or surgical closure could be 
recommended to prevent further residual leakage. Among 
them, the Amplatzer duct occluder, which has been available 
in Japan since 2009, has already been used in patients with a 
large PDA.10–14
Study Limitations
Our study has some limitations. This was a retrospective 
study and had no definite protocol. The indication and tech-
niques used for coil occlusion varied among institutions. 
However, because of the large sample size and good out-
come, our study provides data that can help to determine the 
optimal choice between the 2 devices, namely coils or duct 
occluder for closure of large PDAs.
Conclusion
In conclusion, coil occlusion is an effective and safe proce-
dure for PDA; however, we recommend using devices other 
than coils for closure of a moderate or large PDA. The long-
term outcome is favorable. Further studies are required to 
define the indications that determine which device should be 
used in patients with larger PDAs.
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